Alterity Therapeutics Files 6-K on Unquoted Securities
Ticker: PRNAF · Form: 6-K · Filed: Aug 15, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: securities-filing, unquoted-securities, registration-statement
Related Tickers: ATH
TL;DR
Alterity Therapeutics (ATH) filed a 6-K on Aug 15, 2025, regarding unquoted securities, incorporated into S-8/F-3 filings.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on August 15, 2025, to report information regarding unquoted securities. This filing is incorporated by reference into several of their existing Registration Statements on Form S-8 and Form F-3. The company, formerly known as PRANA BIOTECHNOLOGY LTD, is based in Melbourne, Australia.
Why It Matters
This filing provides updates on the company's securities, which could impact investors' understanding of its capital structure and potential dilution.
Risk Assessment
Risk Level: low — This is a routine filing reporting on securities and is incorporated into existing registration statements, indicating no new immediate risks.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- PRANA BIOTECHNOLOGY LTD (company) — Former Company Name
- August 15, 2025 (date) — Filing Date
- Form S-8 (document) — Incorporated by reference into
- Form F-3 (document) — Incorporated by reference into
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to provide a notification regarding unquoted securities for Alterity Therapeutics Limited (ATH).
When was this Form 6-K filed?
This Form 6-K was filed on August 15, 2025.
Into which existing registration statements is this 6-K filing being incorporated by reference?
This Form 6-K is being incorporated by reference into Alterity Therapeutics Limited's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What was Alterity Therapeutics Limited formerly known as?
Alterity Therapeutics Limited was formerly known as PRANA BIOTECHNOLOGY LTD.
Where is Alterity Therapeutics Limited's principal executive office located?
Alterity Therapeutics Limited's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2025-08-15 07:14:35
Filing Documents
- ea0253488-6k_alterity.htm (6-K) — 14KB
- ea025348801ex99-1_alterity.htm (EX-99.1) — 50KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- 0001213900-25-077038.txt ( ) — 66KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Notification regarding unquoted securities - ATH 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: August 15, 2025 2